GRI Bio to Participate in the Virtual Investor Closing Bell Series
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, announced its participation in the Virtual Investor Closing Bell Series. CEO Marc Hertz, PhD will present on May 28, 2025, at 4:00 PM ET.
The event will include a corporate overview, business outlook, and a live Q&A session with investors. The presentation will be webcast live on the company's website and will remain accessible for 90 days after the event.
GRI Bio (NASDAQ: GRI), un'azienda biotecnologica specializzata nello sviluppo di modulatori delle cellule Natural Killer T (NKT) per malattie infiammatorie, fibrotiche e autoimmuni, ha annunciato la sua partecipazione alla Virtual Investor Closing Bell Series. Il CEO Marc Hertz, PhD terrà una presentazione il 28 maggio 2025 alle 16:00 ET.
L'evento includerà una panoramica aziendale, le prospettive di business e una sessione di domande e risposte dal vivo con gli investitori. La presentazione sarà trasmessa in diretta sul sito web dell'azienda e resterà disponibile per 90 giorni dopo l'evento.
GRI Bio (NASDAQ: GRI), una empresa biotecnológica centrada en el desarrollo de moduladores de células Natural Killer T (NKT) para enfermedades inflamatorias, fibróticas y autoinmunes, anunció su participación en la Virtual Investor Closing Bell Series. El CEO Marc Hertz, PhD presentará el 28 de mayo de 2025 a las 4:00 PM ET.
El evento incluirá una visión general corporativa, perspectivas comerciales y una sesión de preguntas y respuestas en vivo con los inversores. La presentación se transmitirá en vivo en el sitio web de la empresa y estará disponible durante 90 días después del evento.
GRI Bio (NASDAQ: GRI)는 염증성, 섬유증 및 자가면역 질환을 위한 Natural Killer T (NKT) 세포 조절제 개발에 주력하는 생명공학 회사로, Virtual Investor Closing Bell Series에 참여한다고 발표했습니다. CEO Marc Hertz, PhD가 2025년 5월 28일 오후 4시(동부시간)에 발표를 진행할 예정입니다.
이번 행사에서는 회사 개요, 사업 전망, 투자자와의 실시간 질의응답 세션이 포함됩니다. 발표는 회사 웹사이트에서 생중계되며, 행사 후 90일간 다시 볼 수 있습니다.
GRI Bio (NASDAQ : GRI), une entreprise biotechnologique spécialisée dans le développement de modulateurs des cellules Natural Killer T (NKT) pour les maladies inflammatoires, fibreuses et auto-immunes, a annoncé sa participation à la Virtual Investor Closing Bell Series. Le PDG Marc Hertz, PhD présentera le 28 mai 2025 à 16h00 ET.
L'événement comprendra une présentation de l'entreprise, des perspectives commerciales et une session de questions-réponses en direct avec les investisseurs. La présentation sera diffusée en direct sur le site web de la société et restera accessible pendant 90 jours après l'événement.
GRI Bio (NASDAQ: GRI), ein Biotechnologieunternehmen, das sich auf die Entwicklung von Natural Killer T (NKT) Zellmodulatoren für entzündliche, fibrotische und autoimmune Erkrankungen spezialisiert hat, gab seine Teilnahme an der Virtual Investor Closing Bell Series bekannt. CEO Marc Hertz, PhD wird am 28. Mai 2025 um 16:00 Uhr ET präsentieren.
Die Veranstaltung umfasst einen Unternehmensüberblick, einen Ausblick auf das Geschäft und eine Live-Q&A-Session mit Investoren. Die Präsentation wird live auf der Webseite des Unternehmens übertragen und ist 90 Tage nach der Veranstaltung abrufbar.
- None.
- None.
Live webcast on Wednesday, May 28th at 4:00 PM ET
LA JOLLA, CA, May 21, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in the Virtual Investor Closing Bell Series on Wednesday, May 28, 2025 at 4:00 PM ET.
As part of the event, Dr. Hertz will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
A live video webcast will be available on the Events page under the Investors section of the Company’s website (gribio.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of Natural Killer T (“NKT”) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (“dNKT”) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com
FAQ
When is GRI Bio (NASDAQ: GRI) presenting at the Virtual Investor Closing Bell Series?
Who will be presenting for GRI Bio at the Virtual Investor Closing Bell Series?
What therapeutic areas does GRI Bio focus on?
How long will the GRI Bio Virtual Investor Closing Bell Series webcast replay be available?
